National Healthcare Corp
3 nominees · 2 ballot items.
Proposal 1: Re-elect three directors (Emil E. Hassan, Lisa Piercey, M.D., and William A. Adams); Proposal 2: Advisory (non-binding) approval of executive compensation (say-on-pay).
Follow how the vote landed and what changed on National Healthcare Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot2
- 1
Election of Directors
ManagementBoard: FORRe-election of Emil E. Hassan, Lisa Piercey, M.D., and William A. Adams as directors to hold office for three-year terms until their successors are elected and qualified.
- 2
Advisory Vote on Compensation of our Named Executive Officers (Say-On-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis and related tables.
More detail
This management proposal requests an annual, non-binding advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in the proxy (the so-called 'say-on-pay'). Management frames the proposal as a holistic endorsement of its compensation philosophy, which ties a significant portion of pay to company financial performance and individual performance metrics, with bonuses paid 80% in cash and 20% in restricted stock and long-term equity incentives via option grants. The Board is seeking shareholder approval to validate its pay practices and to continue using the existing incentive structures (including the NHC Executive Officer Performance Based Compensation Plan and the 2020 Omnibus Equity Incentive Plan) that the company says align executives’ interests with long-term shareholder value. Management emphasizes governance safeguards—independent committee oversight, benchmarking to peer practices, and prior high shareholder support (over 96% in 2025)—to justify the program and the Board’s recommendation. The proposal is advisory only and will not be binding, but the Board commits to review shareholder voting results and consider them in future compensation decisions, indicating potential responsiveness to investor feedback. Governance-relevant context includes the Company’s pay-for-performance links (bonus pool defined as 5% of pre-tax earnings) and equity vesting schedules, as well as absence of employment agreements and the presence of clawback and insider trading/hedging policies. A sophisticated evaluation should weigh the strong historical shareholder support and clear performance links reported by management against factors such as the outsized pay realized by executives in high-performance years, the limited detail on peer group selection and comparator positioning, and whether the equity and bonus structures sufficiently address long-term risk-taking incentives. The advisory nature of the vote means shareholders must use it as a signaling mechanism rather than a direct control; management’s commitment to consider the outcome reduces but does not eliminate agency risk.
Nominees on the ballot3
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.5% | 1,324,619 | $212M |
| 2 | Morgan Stanley Institutional Investment Advisors LLC | 6.7% | 1,038,804 | $166M |
| 3 | DIMENSIONAL FUND ADVISORS LP | 5.8% | 908,775 | $145M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.1% | 789,421 | $126M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 549,548 | $88M |
| 6 | FIRST TRUST ADVISORS LP | 3.4% | 530,302 | $85M |
| 7 | STATE STREET CORP | 3.1% | 491,575 | $79M |
| 8 | M Holdings Securities, Inc. | 3.0% | 462,411 | $74M |
| 9 | BlackRock, Inc. | 2.5% | 387,018 | $62M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 2.1% | 335,517 | $54M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at National Healthcare Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the National Healthcare Corp 2026 annual meeting?
- National Healthcare Corp (NHC) holds its 2026 annual shareholder meeting on Thursday, May 7, 2026.
- What is the record date for the National Healthcare Corp 2026 meeting?
- The record date for the National Healthcare Corp 2026 meeting is Friday, March 13, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for National Healthcare Corp's 2026 meeting?
- The board is presenting 3 director nominees at the National Healthcare Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the National Healthcare Corp 2026 meeting?
- Shareholders will vote on 2 proposals at the National Healthcare Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.